Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry

Study Overview
=================
Brief Summary
-----------------
The purpose of this registry is to address optimal platelet inhibition during the early management of MI patients prior to coronary angiography or CABG.

Detailed Description
-----------------
The CAMEO registry is a multicenter observational registry that will collect information on 4,000 patients with NSTEMI or STEMI treated with cangrelor or an oral P2Y12 inhibitor into the registry. Phase 1: Each site will abstract data from the medical record for the first 50 patients meeting the inclusion and exclusion criteria treated at the hospital within 4 months prior to study initiation or during the study period. Phase 2: After Phase 1, all cangrelor-treated patients meeting the inclusion and exclusion criteria treated at the hospital no later than 1 month from the discharge date will be entered into the registry, and we will begin sampling non-cangrelor patients in a 2:1 cangrelor: non-cangrelor ratio.

Official Title
-----------------
Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry

Conditions
-----------------
Myocardial Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Phase 1 Inclusion Criteria: For the first 50 patients at each participating site, consecutive patients are entered in the registry if they are ≥ 18 years of age, underwent coronary angiography for a STEMI or NSTEMI, and received cangrelor at any time during the hospitalization or an oral P2Y12 inhibitor during his/her first 48 hours of the hospitalization for MI. Phase 2 Inclusion Criteria: Subsequent patients are eligible to be entered in the registry if they are ≥ 18 years of age and underwent coronary angiography for a STEMI or NSTEMI and meet at least 1 of the following criteria: The patient was hospitalized for STEMI and met one of the following inclusion criteria: The patient received cangrelor at any time during his/her hospitalization for MI. The patient received an oral P2Y12 inhibitor during his/her first 48 hours of hospitalization AND either of the following: The patient received a P2Y12 inhibitor and an opiate/opioid within 24 hours prior to or during primary PCI for STEMI presentation. OR The patient underwent coronary angiography followed by CABG during the index MI admission and received any P2Y12 inhibitor within 7 days prior to CABG. The patient was hospitalized for NSTEMI and met one of the following inclusion criteria: The patient received cangrelor during his/her hospitalization for MI. The patient received an oral P2Y12 inhibitor during his/her first 48 hours of hospitalization AND either of the following: The patient underwent coronary angiography followed by CABG during the index MI admission and received any P2Y12 inhibitor within 7 days prior to CABG. OR Any 2 of the following criteria without prior PCI or CABG: age> 60 years, male sex, diabetes, EF <40% prior heart failure Exclusion Criteria: If the patient does not meet the inclusion criteria for either Phase.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| STEMI/NSTEMI<br>Patients in the registry will be 18 years of age or older and underwent coronary angiography for a ST-elevation myocardial infarction (STEMI) or NSTEMI Non-ST-elevation myocardial infarction | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of Antiplatelet medications used during hospitalization | Antiplatelet use, including switching and discontinuation will be measured by medical record report. The medical record report will include medication start and stop dates and times. | The time frame is hospitalization through discharge, approximately 3 days | 
| Number of bleeding events during hospitalization as measured by medical record report | Bleeding event entered from the medical record report. | The time frame is hospitalization, up to 7 days post discharge | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cangrelor